The Latest Trading Price of Ajanta Pharma Ltd is ₹ 3211 as of 18 May 15:30
. The P/E Ratio of Ajanta Pharma Ltd changed from 23.9 on March 2021 to 35.7 on March 2025 . This represents a CAGR of 8.36% over 5 yearsThe P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Ajanta Pharma Ltd changed from ₹ 15517 crore on March 2021 to ₹ 32708 crore on March 2025 . This represents a CAGR of 16.08% over 5 yearsThe Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Ajanta Pharma Ltd for the Mar '26 is ₹ 1483 crore as compare to the Dec '25 revenue of ₹ 1399 crore. This represent the growth of 5.95% The revenue of Bharat Immunological & Biological Corporation Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ajanta Pharma Ltd for the Mar '26 is ₹ 394.84 crore as compare to the Dec '25 ebitda of ₹ 407.21 crore. This represent the decline of -3.04% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ajanta Pharma Ltd changed from ₹ 245.77 crore to ₹ 266.7 crore over 8 quarters. This represents a CAGR of 4.17%
The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0%
The Dividend Payout of Ajanta Pharma Ltd changed from 12.23 % on March 2021 to 38.28 % on March 2025 . This represents a CAGR of 25.63% over 5 yearsThe Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .
About Ajanta Pharma Ltd
Ajanta Pharma Limited is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa.
The Company is involved in development, manufacturing and marketing of quality finished dosages in domestic and international markets.
It produces a comprehensive range of specialty products targeting different therapeutic segments.
It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market.
The company's business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.
The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia.
About Bharat Immunological & Biological Corporation Ltd
The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets.
The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96.
The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.
FAQs for the comparison of Ajanta Pharma Ltd and Bharat Immunological & Biological Corporation Ltd
Which company has a larger market capitalization, Ajanta Pharma Ltd or Bharat Immunological & Biological Corporation Ltd?
Market cap of Ajanta Pharma Ltd is 40,117 Cr while Market cap of Bharat Immunological & Biological Corporation Ltd is 75 Cr
What are the key factors driving the stock performance of Ajanta Pharma Ltd and Bharat Immunological & Biological Corporation Ltd?
The stock performance of Ajanta Pharma Ltd and Bharat Immunological & Biological Corporation Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.
What are the recent stock price for Ajanta Pharma Ltd and Bharat Immunological & Biological Corporation Ltd?
As of May 18, 2026, the Ajanta Pharma Ltd stock price is INR ₹3211.05. On the other hand, Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.47.
How do dividend payouts of Ajanta Pharma Ltd and Bharat Immunological & Biological Corporation Ltd compare?
To compare the dividend payouts of Ajanta Pharma Ltd and Bharat Immunological & Biological Corporation Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.